Calendario›CGEN›COM701 · MAIA-ovarian
COM701 · MAIA-ovarian
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Ensayo de COMPUGEN LTD en Ovarian Cancer · Ovarian Cancer Recurrent (del registro, en inglés).
Más ensayos de: Cáncer de ovario.
- Fase
- Fase 1/2
- Estado
- Reclutando pacientes
- Participantes
- 60
- Centros
- 28
- Fin del objetivo primario
- mar 2027
Qué significa cada fase y cada estado.
Estudio de intervención, aleatorizado, triple ciego. Comenzó en jul 2025.
Qué mide
To evaluate the effect of COM701 as a single agent on progression free survival when administered as a maintenance regimen in participants with relapsed PSOC (From the date of randomization until the date of disease progression, or date of death from any cause whichever occurs first, assessed up to 2 years) (del registro, en inglés)
Qué se prueba
Se prueba el anticuerpo COM701 en pacientes con cáncer de ovario recidivante y sensible al platino, para ver si retrasa la progresión de la enfermedad y evaluar su seguridad.
Lo que dice el documentoThe goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701.
Traducción automática (claude-sonnet-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,
Más ensayos de CGEN
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| COM503 | Fase 1 | Reclutando pacientes | nov 2027 (prevista) |
| Dose escalation: COM902… | Fase 1 | Completado | abr 2026 (real) |
| COM701 in combination with… | Fase 1/2 | Completado | may 2024 (real) |
| COM701 | Fase 1 | Completado | ene 2024 (real) |
Todos los de CGEN, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06888921), actualizada en sep 2026.